Patrik Renblad
Director of Finance/CFO bei CANTARGIA AB
Profil
Patrik Renblad is currently the Chief Financial Officer at Cantargia AB since 2023.
Prior to this, he was the Chief Financial Officer at SynAct Pharma AB from 2022 to 2023.
He also worked as a Finance Director-R&D at LEO Pharma A.
Mr. Renblad is a graduate of the University of Lund.
Aktive Positionen von Patrik Renblad
| Unternehmen | Position | Beginn |
|---|---|---|
| CANTARGIA AB | Director of Finance/CFO | 15.06.2023 |
Ehemalige bekannte Positionen von Patrik Renblad
| Unternehmen | Position | Ende |
|---|---|---|
| SYNACT PHARMA AB | Director of Finance/CFO | 15.05.2023 |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Corporate Officer/Principal | - |
Ausbildung von Patrik Renblad
| University of Lund | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CANTARGIA AB | Health Technology |
| SYNACT PHARMA AB | Health Technology |
| Private Unternehmen | 1 |
|---|---|
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Health Technology |
